Istituto Superiore di Sanità (ISS), - EpiCentro – L’epidemiologia per la sanità pubblica. Broncopneumopatia cronica ostruttiva. Online https://www.epicentro.iss.it/broncopneumopatia/ (Accessed May 2024)

National Heart, Lung, and Blood Institute. What is COPD? Online https://www.nhlbi.nih.gov/health/copd. (Accessed May 2024)

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 Report. Online https://goldcopd.org/2023-gold-report-2/ (Accessed May 2024)

Rapporto Osservasalute 2022. Stato di salute e qualità dell’assistenza nelle regioni italiane. Online https://osservatoriosullasalute.it/wp-content/uploads/2023/06/ro-2022-volume_completo.pdf (Accessed May 2024)

National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Online https://www.nice.org.uk/guidance/ng115/chapter/recommendations (Accessed May 2024)

Ministero della Salute. La continuità assistenziale: Broncopneumopatia Cronica Ostruttiva (BPCO). Online https://www.salute.gov.it/imgs/C_17_pubblicazioni_1893_allegato.pdf. (Accessed May 2024)

IQVIA. Gestione della BPCO in Italia: impatto della pandemia e della Nota 99 sull’assistenza terapeutica. Online https://www.iqvia.com/-/media/iqvia/pdfs/italy/publications/01_bife_gsk_gestione_della_bpco_in_italia.pdf (Accessed May 2024)

National Heart, Lung, and Blood Institute. Treatment COPD. Online https://www.nhlbi.nih.gov/health/copd/treatment. https://www.iqvia.com/-/media/iqvia/pdfs/italy/publications/01_bife_gsk_gestione_della_bpco_in_italia.pdf (Accessed May 2024)

Agenzia Italiana del Farmaco (AIFA). AIFA pubblica la Nota 99 per la prescrizione dei farmaci per la BPCO. Online https://www.aifa.gov.it/-/aifa-pubblica-la-nuova-nota-99-per-la-prescrizione-dei-farmaci-per-la-bpco (Accessed May 2024)

Agenzia Italiana del Farmaco (AIFA). L’uso dei farmaci in Italia – Rapporto Nazionale Anno 2022. Online https://www.aifa.gov.it/documents/20142/1967301/Rapporto-OsMed-2022.pdf. (Accessed May 2024)

Mannino D, Bogart M, Wu B, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respir Med. 2022;197:106807. PMID:35429764 https://doi.org/10.1016/j.rmed.2022.106807 PMID:35429764

Agenzia Italiana del Farmaco (AIFA). Aderenza alle terapie e strategie per migliorare l’uso sicuro ed efficace dei farmaci. Online https://www.aifa.gov.it/-/aderenza-alle-terapie-e-strategie-per-migliorare-l-uso-sicuro-ed-efficace-dei-farmaci (Accessed May 2024)

Istituto Nazionale di Statistica (ISTAT). Popolazione residente al 1° gennaio: Per fascia di età. Online http://dati.istat.it/Index.aspx?QueryId=42869 (Accessed May 2024)

Global Initiative for Chronic Obstructive Lung Disease. Strategia Globale per la diagnosi, il trattamento e la prevenzione della BPCO – Revisione 2017. Online https://goldcopd.it/wp-content/uploads/materiali/2017/GOLD_Pocket_2017.pdf (Accessed May 2024)

Soriano JB, Hahsler M, Soriano C, et al; CHAIN investigators. Temporal transitions in COPD severity stages within the GOLD 2017 classification system. Respir Med. 2018;142:81-85. https://doi.org/10.1016/j.rmed.2018.07.019 PMID:30170807

Wallace AE, Kaila S, Bayer V, et al. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population. J Manag Care Spec Pharm. 2019;25(2):205-217. PMID:30698096 https://doi.org/10.18553/jmcp.2019.25.2.205 PMID:30698096

Johansson G., Mushnikov V., Bäckström T., et al. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm Med. 2018 Jan 25;18(1):17. https://doi.org/10.1186/s12890-018-0573-0 PMID: 29370846

Miravitlles M, Kostikas K, Bizymi N, Tzanakis N. A Novel Figure and Algorithm for the Gold ABE Classification. Arch Bronconeumol. 2023;59(11):702-704. https://doi.org/10.1016/j.arbres.2023.06.001 PMID:37355409

Palmiotti GA, Lacedonia D, Liotino V, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455-2462. https://doi.org/10.2147/COPD.S157779 PMID:30147311

Agenzia Italiana del Farmaco (AIFA). Domande e risposte relative all’applicazione della Nota 99 per la prescrizione dei farmaci inalatori indicati nella terapia di mantenimento della BPCO. Online https://www.aifa.gov.it/documents/20142/1728122/FAQ_Nota_99_BPCO_15.11.2022.pdf (Accessed May 2024)

Weir DL, Bai YQ, Thavorn K, Guilcher S et al. Non-adherence to COPD medications and its association with adverse events: A longitudinal population based cohort study of older adults. Ann Epidemiol. 2024 Aug;96:88-96. https://doi.org/10.1016/j.annepidem.2023.12.003. PMID: 38141744

Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435-441. PMID:20880687 https://doi.org/10.1016/j.rmed.2010.09.006 PMID:20880687

Strange C, Tkacz J, Schinkel J, et al. Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: results from the EROS (US) Study. Int J Chron Obstruct Pulmon Dis. 2023;18:2245-2256. https://doi.org/10.2147/COPD.S432963 PMID:37849918

Ministero della Salute. Tariffario delle prestazioni di assistenza ambulatoriale. Online http://www.salute.gov.it/portale/temi/p2_6.jsp?id=1767&area=programmazioneSanitariaLea&menu=lea (Accessed May 2024)

Koleva D, Motterlini N, Banfi P, Garattini L; Study Group BIC. Healthcare costs of COPD in Italian referral centres: a prospective study. Respir Med. 2007;101(11):2312-2320. PMID:17681461 https://doi.org/10.1016/j.rmed.2007.06.020 PMID:17681461

Istituto Nazionale di Statistica (ISTAT). Rivalutazioni e documentazione su prezzi, costi e retribuzioni contrattuali. https://rivaluta.istat.it/ (Accessed May 2024)

Kendall R, Martin AA, Shah D, Shukla S, Compton C, Ismaila AS. Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. Int J Chron Obstruct Pulmon Dis. 2023;18:1815-1825. PMID:37636901 https://doi.org/10.2147/COPD.S400707 PMID:37636901

Rettifica decreto commissariale N°U00265 1° settembre 2014. Online https://www.regione.lazio.it/sites/default/files/decreti-commissario-ad-acta/SAN_DCA_U00064_18_02_2015.pdf. (Accessed May 2024)

Agenzia Italiana del Farmaco (AIFA). Elenco dei Farmaci di Fascia A per principio attivo. Online https://www.aifa.gov.it/liste-farmaci-a-h. (Accessed May 2024)

Agenzia Italiana del Farmaco (AIFA). Elenco dei Farmaci di Fascia H per principio attivo. Online https://www.aifa.gov.it/liste-farmaci-a-h. (Accessed May 2024)